openPR Logo
Press release

Parkinson’s Disease Therapeutic Market- Trends, Outlook 2025

02-07-2018 03:20 PM CET | Health & Medicine

Press release from: Pharmaceutical & Healthcare

Parkinson’s Disease Therapeutic Market- Trends, Outlook

Parkinson’s disease (PD) is a chronic disorder characterized by the malfunctioning and death of vital nerve cells in the brain, and can be characterized by tremor, dementia, and depression. Parkinson’s disease progression leads to uncontrolled body movement of the patient. There is no cure presently for parkinson’s disease only treatments options such as medication and surgery to manage the symptoms are available. Parkinson’s disease mainly affects people over 50 and the risk increases with increasing age. Parkinson’s disease treatment is used to control symptoms such as uncontrolled movement, shakiness of hands, and some others. The therapeutic approaches like levodopa in combination with carbidopa is considered as an effective treatment over symptoms of Parkinson’s disease. The surgical treatment option is available but it is only effective for patients who are previously responded to levodopa therapy. The research and development in the field of Parkinson’s disease therapeutic will help in the treatment of Parkinson’s disease.

Increase in prevalence of Parkinson’s disease across the world is driving the Parkinson’s disease therapeutic market

According to Parkinson’s disease foundation, more than 10 million people globally are living with Parkinson’s disease and 60,000 Americans are diagnosed with Parkinson’s disease each year. The rising prevalence of Parkinson’s disease across the world is one of the major factor which is driving the Parkinson’s disease therapeutic market. Rising male patients, is also the major factor owing to Parkinson’s disease therapeutic market, because as mentioned in the data of Parkinson’s disease foundation, chances of getting Parkinson’s disease are one and half times more in men than women. The increase in number of geriatric population and technological advancements such as combination therapies for prolong action of continuous dopaminergic stimulation drugs, gene therapy, neural transplantation are some other causes which are likely to drive the Parkinson’s disease therapeutic market. However some restraints like expiry of patents for several drugs such as Stalevo, Azilect, Rytary, Comtan etc. can cause the cessation of Parkinson’s disease therapeutic market.

The advancements in medical devices segment for Parkinson’s disease treatment is expected to boost the growth in Parkinson’s disease therapeutic market

Global Parkinson’s disease therapeutic market is segmented on the basis of treatment type, end user and geographical regions

Request For Sample Copy@
https://www.coherentmarketinsights.com/insight/request-sample/494

On the basis of treatment type:

Medical Devices
Deep Brain Stimulation (DBS) Devices
Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices
Drug Class
Dopamine precursors
COMT Inhibitors
MAO Inhibitors
Peripheral Decarboxylase Inhibitors
Others
On the basis of end user:

Clinics
Hospitals
Homecare Settings
New advancements in the treatment of parkinson’s disease has helped to boost the growth in North America for parkinson’s disease therapeutic market.

Regional segmentation of Parkinson’s disease therapeutic market according to coherent market Insights comprises of North America, Latin America, Europe, Asia pacific, Middle East, and Africa. High prevalence of Parkinson’s disease and good reimbursement policies are some of factors which allows the North America region to dominate in the Parkinson’s disease market. For instance, over 40 medicines are developed for the treatment of parkinsons disease and many have gained the fast track designation from U.S. Food and Drug Administration (FDA) in North America. North America is expected to hold the largest share in the Parkinson’s disease market because of increase in investments in research and development for Parkinson’s disease.

New product development is the key strategy adopted by major industry player in Parkinson’s disease therapeutic market

Key players in the Parkinson’s disease therapeutics market globally are Salix Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., Mylan N.V., Orion Corporation, Boehringer Ingelheim, UCB, and Impax Labs. Many of the key players involved in the anti-Parkinson’s disease medication and some of the biopharmaceuticals research companies in the U.S. are currently in the development of new medicines for treatment of Parkinson’s disease. The industry players such as Novartis AG, Pfizer, Ceregene, and Biogen are expected to launch new drugs for Parkinson’s disease treatment in the future.

Get More Details On this Report:
https://www.coherentmarketinsights.com/ongoing-insight/parkinsons-disease-therapeutic-market-494

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Parkinson’s Disease Therapeutic Market- Trends, Outlook 2025 here

News-ID: 935742 • Views: 394

More Releases from Pharmaceutical & Healthcare

Erectile Dysfunction: A Prominent Age Related Disorder
Erectile dysfunction is known as the medical condition of penis, a recurrent inability of a man to reach and/or to maintain a penile erection sufficient for/during sexual activities. It is most probably an age-related factor, progressive condition, affecting some level of disorder (mild, moderate or severe) in about 50% of men aged 40-70 years, and with the increase in the age, severity of erectile dysfunction also increase with a
Peanut Allergy Vaccine Market – Global Industry Insights, Trends, 2024
Allergies are medical conditions caused primarily by hypersensitivity of the immune system to some external stimulus. Allergy may cause anaphylaxis—a medical condition that can cause irritation of the skin, swelling of throat, shortness of breath, and in some cases, death. Allergies are caused by various allergens such as pollen grains, or certain foods such as peanuts. Vaccination is the process of administering antigenic material or a vaccine to stimulate one’s
Parkinson’s Disease Therapeutic Market — Global Industry Insights, Trends, O …
Parkinson’s disease (PD) is a chronic disorder characterized by the malfunctioning and death of vital nerve cells in the brain, and can be characterized by tremor, dementia, and depression. Parkinson’s disease progression leads to uncontrolled body movement of the patient. There is no cure presently for parkinson’s disease only treatments options such as medication and surgery to manage the symptoms are available. Parkinson’s disease mainly affects people over 50 and
Global Veterinary Vaccines Market Insights 2024
Increasing incidence of veterinary diseases to drive the growth of veterinary vaccines market According to the 2015 Global Animal Disease Intelligence Report by the Food and Agriculture Organization (FAO), prevalence of foot-and-mouth disease (FMD) was especially high in Morocco, Saudi Arabia, Turkey, Northern, and Southern Africa. Ebola (Zoonotic disease) continued to be prevalent in West Africa. Also, rabies that leads to thousands of human deaths worldwide is prevalent in 150 countries

All 5 Releases


More Releases for Parkinson’s

Parkinson’s disease Therapeutics Parkinson’s disease Therapeutics Market to …
This report studies the global Parkinson's Disease Therapeutics market, analyzes and researches the Parkinson's Disease Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like GSK Novartis Boehringer Ingelheim Teva Pharmaceutical Abbvie ….. Ask for sample copy @ https://www.researchtrades.com/request-sample/1199125 Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Market segment by Type, Parkinson's Disease Therapeutics can be split into Medications Therapeutics Medical Devices Therapeutics Buy
US Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in the United States in recent years and it most likely to continue rising in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. The society pays a significant amount towards treating this disease in the country. It is estimated that the total cost to the nation exceeds
Europe Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson’s disease. This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer’s disease), Parkinson’s is the second most common and it is expected that
Parkinson’s Disease - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Parkinson’s Disease - Heat Map and Analysis to its growing collection of premium market research reports. Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive loss of muscular control, leading to resting tremor, rigidity, akinesia and postural reflex impairment. PD is an age-related disorder; symptoms typically begin to first appear in patients in their mid-sixties,
New Education Options for Parkinson’s Caregivers
(4/30/2012- Gilbert, Ariz.) When a loved one is diagnosed with Parkinson’s Disease (PD), it becomes clear that Parkinson’s is a life- changing experience for the entire family — particularly for the primary care provider, who is most often a spouse, child or parent. Family caregivers may not think of themselves as a care providers or recognize their new caregiving tasks. As family members begin helping with doctor visits, taking over financial
StemGenex™ Offers Therapy for Parkinson’s Disease
Treatment for U.S. citizens battling Parkinson’s disease is closer than most people think. La Jolla, CA, April 03, 2012 -- Parkinson's disease is becoming plague-like. One million Americans currently suffer from the disease, resulting in 25 billion dollars spent on medical research and treatment annually. According to the National Parkinson's Foundation, each patient spends an average of $2,500 a year for medications. Estimates of costs of medical care, disability payments and